Lectures: course of Pathophysiology for General medicine 3rd Year of Medical faculty

PATHOPHYSIOLOGY
Inborn metabolic disorders 1

Roman Benacka, MD, PhD,

Department of Pathophysiology,

P.J. Safarik University, Košice, SVK

Disorders of carbohydrate metabolism

Galactosemia

- Group of AR-disorders caused by defects in the pathway for hepatic conversion of galactose to glucose, Enzymes involved are following:
  - galactokinase (GALK), galactose-1-phosphate;
  - uridyltransferase (GALT),
  - UDP galactose-4-epimerase

Classic galactosemia (GALT deficiency)

- the most common, the most severe; galactose-1-phosphate cummulates in liver -> resulting in hepatic damage (fatty liver = steatosis; latter fibrotic liver = cirrhosis)
- Cummulates in brain (intellectual impairment; speech delay, learning difficulties) + renal tubules (dysfunction); ovarian failure
- Upon exposure to lactose in milk: vomiting, jaundice, hepatomegaly within a few weeks of birth + may predispose to E.coli sepsis
- Cataracts due to galactitol accumulation in the lens.
- **T:** lactose-free diet, which
- **Dg:** galactose-1-phosphate in red blood cells; elevated urine galactitol.



Disorders of carbohydrate metabolism

Glycogen storage diseases (glycogenoses)

D: Glycogen storage diseases (GSD) is a group of disorders caused by enzyme defects in the processing of synthesis / or breakdown of glycogen in the muscles, liver, and other cells

PA: Disorders are characterized by accummulation of abundant glycogen in original places (liver, muscles) or extra locations (e.g. spleen, other organs)

- GSD are mostly genetic; but also exist as acquired ones (intoxication with the alkaloid *castanospermine*)

OCC: incidency in EU 1: 40,000; in US 1: 20,000-25,000 births; individuals;

Now the group inlcudes 11 distinct diseases (some previously thought to be distinct have been reclassified). Although glycogen synthase deficiency does not result in storage of extra glycogen in the liver, it is often classified with the GSDs as type 0 because it is another defect of glycogen storage and can cause similar problems.)

- **Hypoglycaemic: GSD type 0, I, III, VI, IX, XI**
- **Hepatomegaly: GSD type I, II, III, IV, VI, IX**
- **Hyperlipidemia: I, III**
- **Muscular: GSD type II, 0 , III, V, VII, XII, XIII**
- usually present in childhood, although some, such as McArdle disease and Pompe disease, have separate adult-onset forms.


Glycogen
Debrancher enzyme
GSD III
Phosphorylase
GSD V
Brancher enzyme
Acid maltase
GSD II
Glucose
Hexokinase
Fructose
Fructokinase
Glucose-1-6-phosphate
Glucose-6-phosphate
Fructose-6-phosphate
GSD VII
Fructose-1-6-phosphate
Citric acid cycle
ADP
ATP

Type	Eponym	Enzyme deficiency	Symptoms
GSD type 0	--	glycogen synthase	Occasional muscle cramping, Hypoglycemia,
GSD type I	**von Gierke's disease 1: 50,000- 100,000**	glucose-6-phosphatase	Hypoglycemia, Hepatomegaly Growth failure, Lactic acidosis hyperuricemia
GSD type II	**Pompe's disease 1 in 40,000**	acid alpha-glucosidase	Hepatomegaly, Muscle weakness Death by age ~2 years heart failure
GSD type III	**Forbes - Cori's disease 1 in 100,000**	glycogen debranching enzyme	Hepatomegaly, Myopathy
GSD type IV	**Andersen disease**	glycogen branching enzyme	cirrhosis Failure to thrive, death at age ~5 years
GSD type V	**McArdle disease 1 in 100,000**	muscle glycogen phosphorylase	Exercise-induced cramps Rhabdomyolysis Renal failure by myoglobinuria
GSD type VI	**Hers' disease 1 in 65,000- 85,000**	liver glycogen phosphorylase	
GSD type VII	**Tarui's disease**	muscle phosphofructokinase	Exercise-induced muscle cramps and weakness Haemolytic anaemia growth retardation
GSD type IX		phosphorylase kinase, PHKA2	Delayed motor development, Growth retardation
GSD type XI	**Fanconi-Bickel syndrome**	glucose transporter GLUT2	
GSD type XII	**Red cell aldolase deficiency**	Aldolase A	Exercise intolerance, cramps
GSD type XIII		β-enolase	Increasing intensity of myalgias over decades Serum CK: Episodic elevations Exercise intolerance, cramps



HEPATIC FORMS

Glycogen storage disease type I (Von Gierke disease

- two subtypes type 1a and type 1b
- clinical hallmarks:
  - **neonatal hypoglycemia**
  - **enlargement of the liver** (glycogen accumulation)
  - Intracelullar accumulation of glycogen





HEPATIC FORMS

A fatty liver can lead to cirrhosis and liver malfunction if not controlled.







Too much fat in liver cells

Symptoms may include tiredness and belly pain, but often fatty liver is not noticed until a blood test is done.



The liver may also be larger than normal.



MUSCULAR FORMS

Glycogen storage disease type II (Pompe ‘s disease; acid maltase deficiency)

- AR ; the only glycogen storage disease with a defect in lysosomal metabolism; African Americans:1: 14,000-40,000; China and Taiwan, : most common GSD 1 in 50,000
- first glycogen storage disease identified, in 1932 by the Dutch pathologist J.C.Pompe.
- accumulation of glycogen in skeletal muscles; progressive muscle weakness (myopathy)
- heart, liver and nervous system.





MUSCULAR FORMS

- **McArdle disease (Type V Glycogen Storage Disease**
- GSDs are found in 2-3 children per 100,000 births per year.
- Initial symptoms are cramps, stiffness, fatigue, and pain after exerc progressive proxima weakness after exc
- fixed motor weakne







Frozen section of muscle tissue reveals "empty" sub-sarcolemmal vacuoles (H and E stain).



Frozen section of muscle tissue shows PAS-positive deposits of glycogen (PAS stain).



Positive staining for phosphorylase in normal muscle

McArdle disease: complete lack of staining for

Carbohydrate metabolism

Mucopolysaccharidoses [ICD-10 E76; ICD-9 277.5]

Df: metabolic disorders (part of the lysosomal storage disease family) caused by the absence or abnormal function of one of t'he ysosomal enzymes (altogether 11) involved in breakdown of **glycosaminoglycans** (these collect in the cells, blood and connective tissues) and result in skeletal organ, mental defects

Glycosaminoglycans (formerly mucopolysaccharides) = long chain carbohydrates in ECM (bone, cartilage, tendons, corneas, skin, joints, and loose connective tissue)

Sy: Share many clinical features but have varying degrees of severity: May not be apparent at birth but progress as storage of glycosaminoglycans affects bone, skeletal structure, connective tissues, and organs.

- **Skeletal abnormamities** : rough facial features (including a flat nasal bridge, thick lips, and enlarged mouth and tongue), short stature with disproportionately short trunk (dwarfism), dysplasia (abnormal bone size and/or shape) and other skeletal irregularities, claw-like hands progressive joint stiffness
- thickened skin, hepatomegaly) splenomegaly), hernias, and excessive body hair growth.

(cont on other slide ->)



Type	Common name /Other names		Gene (Locus) Incidence	Deficient enzyme	Accum, products	Symptoms
MPS IH MPS IS	Hurler syndrome Scheie syndrome Mucopolysaccharidosis type V	AR	IDUA 4p16.3 1:100,000;	α-L-iduronidase	Heparan sulfate Dermatan sulfate	Mental retardation, micrognathia, coarse facial features, macroglossia, retinal degeneration, corneal clouding, cardiomyopathy, hepatosplenomegaly;
MPS II	Hunter syndrome	X	IDS Xq28 1:250,000	Iduronate sulfatase	Heparan sulfate Dermatan sulfate	Mental retardation (similar, but milder, symptoms to MPS I). This type exceptionally has X-linked recessive inheritance
MPS IIIA	Sanfilippo syndrome A 1:280,000	AR	SGSH 17q25.3	Heparan sulfamidase	Heparan sulfate	Developmental delay, severe hyperactivity, spasticity, motor dysfunction, death by the second decade
MPS IIIB	Sanfilippo syndrome B 1:50,000	AR	NAGLU 17q21.2	N-acetylglucosaminidase		
MPS IIIC	Sanfilippo syndrome C	AR	HGSNAT 8p11.21	Heparan-α-glucosaminide N-acetyltransferase		
MPS IIID	Sanfilippo syndrome D	AR	GNS 12q14.3	N-acetylglucosamine 6-sulfatase		
MPS IVA	Morquio syndrome A	AR	GALNS 16q24.3 1 in 75,000	Galactose-6-sulfate sulfatase	Keratan sulfate	Severe skeletal dysplasia, short stature, motor dysfunction Chondroitin 6-sulfate
MPS IVB	Morquio syndrome B	AR	GLB1 3p22.3	β-galactosidase	Keratan sulfate	

MPS VI	Maroteaux–Lamy syndrome	AR	ARSB 5q14.1	N-acetylgalacto-samine- 4-sulfatase	Dermatan sulfate	Severe skeletal dysplasia, short stature, motor dysfunction, kyphosis, heart def.
MPS VII	Sly syndrome	AR	GUSB 7q11.21 <1:250,000	β-glucuronidase	Heparan sulfate Dermatan sulfate	Hepatomegaly, skeletal dysplasia, short stature, corneal clouding, developmental delay Chondroitin 4,6-sulfate
MPS IX	Natowicz syndrome Hyaluronidase deficiency	AR	HYAL1 3p21.31	Hyaluronidase	Hyaluronic acid	Nodular soft-tissue masses around joints, episodes of painful swelling of the masses, short-term pain, mild facial changes, short stature, normal joint movement, normal intelligence

Sy: *(cont.)*

- **Respiratory infections,** obstructive airway disease and obstructive sleep apnea
- **Heart disease,** enlarged or diseased heart valves.
- **Neurological** : compression of nerves or nerve roots in the spinal cord or in PNS

Sy: *(cont.)*

- **Sensory: Hearing loss** - conductive (pressure behind the ear drum), neurosensitive (tiny hair cells in the inner ear are damaged); glaucoma and degeneration of the retina
- **Mental:** normal intellect or cognitive developmental delay, or may have severe behavioral problems.

Hurler syndrome, Hurler's disease
Mucopolysaccharidosis type I (MPS I)

- **E:** deficiency of alpha-L iduronidase -> accumulation of heparan sulfate + dermatan sulfate
  - 3 subtypes based on severity of symptoms; MPS I H Hurler syndrome is the most severe; MPS I S or Scheie syndrome and MPS I H-S or Hurler-Scheie syndrome
  - Gertrud Hurler (1889–1965), a German pediatrician; London, work: "A rare disease in two brothers".
- **CM:**
  - symptoms appear during childhood and early death due to organ damage
  - normal at birth ; diagnosis usually made at 6-24 months: hepatosplenomegaly, corneal clouding, skeletal deformities coarse (**gargoyle like)** facies/ prominent forehead, enlarged tongue nasal discharge
  - dwarfism, hunchback, mental retardation, joint stiffness, protuberant abdomen, umbilical and inguinal hernias
  - hearing loss - sensorineural deafness, noisy breathing,
  - cardiac abnormalities coronary artery thickening, angina pectoris



Hunter syndrome, Mucopolysaccharidosis type II











Df: iduronate 2-sulfatase deficiency, sulfoiduronate sulfatase deficiency, SIDS deficiency, **X-linked recessive**; some cases survive to adulthood

- first described by the Canadian physician Charles H. Hunter (1873-1955)
- two phenotypes: mucopolysaccharidosis type IIA and mucopolysaccharidosis type IIB.

Oc: UK 1: 132,000 male births;
in Israel 1: 34,000.

Sy:

- dwarfism, hepatosplenomegaly and a grotesque facies,
- a pigmentary retinopathy with loss of photoreceptors
- cornea is usually clear,
- mental retardation is not always present



Sanfilippo syndrome (MPS-III)

Df: rare but severe AR – inherited lysosomal storage disease leading to accumulation of glycosamino-glycan heparan sulfate and manifested maily by short status and mental disability..

Oc: for all four types combined ~ 1: 70,000 births; There are 4 different types with diffeent enzyme defect

Sy:

- motor disability + progressive dementia,
- aggressive behavior, hyperactivity,seizures,
- deafness and loss of vision
- inability to sleep for more than a few hours at a time.

Maroteaux-Lamy disease (MPS VI)

Df: severe to mild AR dis, with somatic involvement seen in MPS I, but with good intelligence.

Et: mutations of the ARSB gene (5q11-13 encoding N-acetylgalactosamine-4-sulfatase (arylsulfatase B).

Sy: Severe: growth can be normal for the 1st few years

corneal clouding, coarse facial features, joint stiffness, valvular heart disease, hydrocephalus, and dysostosis multiplex

Mild: Spinal cord compression thickening of the dura in the upper cervical canal with resultant myelopathy

Morquio syndrome (MPS IV)

Df: very rare AR- dis. with 2 types caused by defect of galactose 6-sulfate sulfatase (Type A) or beta-galactosidase (Type B) ;onset 1- 3 year

Sy: progressive skeletal changes: start at age of 18 months, stops completely by the age of 8; severe forms may not live > 20.30 y.

- Dwarfism; bell-shaped chest, flattening or curvature of the spine, shortened long bones, dysplasia of the hips, ankles and wrists, knock-knee, joint stiffness,
- Conductive and/or neurosensitive deafness, corneal clouding intelligence normal;
- Odontoid hypoplasia = defect in bones between the head and neck (need fusion)
- Restricted breathing, and heart disease <- spatial restriction












Comparisons of various MPS - forms



Jürgen Spranger, J.: *Muccopolysaccharidoses, Chapter 88. In: Nelson Textbook of Pediatrics, 18th ed., Kliegman (Ed), 2007*

	MUCOPOLYSACCHARIDOSIS TYPE						
MANIFESTATIONS	I-H	I-S	II	III	IV	VI	VII
Mental deficiency	+	-	±	+	-	-	±
Coarse facial features	+	(+)	+	+	-	+	±
Corneal clouding	+	+	-	-	(+)	+	±
Visceromegaly	+	(+)	+	(+)	-	+	+
Short stature	+	(+)	+	-	+	+	+
Joint contractures	+	+	+	-	-	+	+
Dysostosis multiplex	+	(+)	+	(+)	+	+	+
Leucocyte inclusions	+	(+)	+	+	-	+	+
Mucopolysaccharidiuria	+	+	+	+	+	+	+



Various types of mucopolysaccharidoses. I: Hurler disease, 3 yr; II: Hunter disease, 12 yr; III: Sanfilippo disease, 4 yr; IV: Morquio disease, 10 yr; VI: Maroteaux-Lamy disease, 15 yr

Lipid storage disorders

- **Lipid storage disorde**r **(lipidosis) -** group of inherited metabolic disorders characterized by pathological accumulation of lipids (buildup of fats) in body's cells and tissues (brain, peripheral nervous system, liver, spleen and bone marrow.
- Etio: inherited malfunction or deficiency of lysosomal enyzmes needed to metabolize;

a) AR – inheritance; 25% chance ofdefect; 50% chance of being a carrier, 25% healthy

b) X-linked recessive Boys 50% chance of inheriting the disorder. Daughters have a 50%

- Class: a) sphingolipidoses (sphingolipid metabolism); b) other: fucosidosis, Schindler disease Wolman disease

Sphingolipidoses

- Gangliosidosis
  - GM1 gangliosidoses
    - Niemann-Pick disease
  - GM2 gangliosidoses
    - Tay–Sachs disease
    - Sandhoff disease
    - GM2-gangliosidosis
- Glycolipidoses
  - Globosidosis
    - Fabry's disease
  - Krabbe disease
  - Metachromatic leukodystrophy
- Sphingomyelinosis
  - Niemann–Pick disease (
- Glucocerebrosides
  - Gaucher's disease
- Sphingosinosis
  - Farber disease

Sphingolipidoses

Def: class of lipid storage disorders relating to sphingolipid metabolism: **Niemann-Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease, Metachromatic leukodystrophy, Multiple sulfatase deficiency and Farber disease.**

Class: subdivided into GM1 a G2 gangliosidoses

Etio: mostly AR-ly inherited; Fabry disease is X-linked recessive.

Epi: incidence 1:10.000

Clin: Fabry dis. + Gaucher dis (treated by enzyme replacement therapy) can survive into adulthood; other types generally fatal by age 1-5 y.

- **GM1 gangliosidoses** - deficiency of beta-galactosidase, abnormal storage of acidic lipid CNS and PNS nerve cells.; GM1 has three forms: early infantile, late infantile, and adult
- **GM2 gangliosidoses -** result from a deficiency of lysosomal beta-hexosaminidase (degradation of gangliosides)



Sphingolipid

Name	X=
Ceramide	H
Sphingomyelin	↓–P–↓Choline
	↓–P–↓Ethanolamine
Glucosylcerebroside	—Glc (in non-neural tissue)
Galactocerebroside	—Gal (in neural tissue)
Globosides	several neutral sugars (Glc, Gal, GalNAc)
Gangliosides	complex carbohydrates:

GM: single NANA
GD: two NANA
GT: three NANA
GQ: four NANA



N-acetylneuraminic acid (NANA)

Sphingolipidoses

Disease	Deficient enzyme[1]	Accumulated products[	Symptoms
Niemann-Pick disease	Sphingomyelinase	Sphingomyelin (brain , erythrocytes)	**Autosomal recessive;** 1 :100,000 Mental retardation, Spasticity, Seizures Hepatosplenomegaly, Thrombocytopenia, Ataxia
Fabry disease	α-galactosidase A	Glycolipids, particularly ceramide trihexoside, in brain, heart, kidney	**X-linked,** 1:40,000 to 1: 120,000 Infarction in affected organs; Acroparesthesia Angiokeratomas , Hypohidrosis
Krabbe disease	Galactocerebrosidase	Glycolipids, particularly galactocerebroside, in oligodendrocytes	**Autosomal recessive;** 1: 100,000 Spasticity, Neurodenegeration (leading to death) Hypertonia ,Hyperreflexia, Decerebration - like posture, Blindness ,Deafness
Gaucher disease	Glucocerebrosidase	Glucocerebrosidesin RBCs, liver and spleen	**Autosomal recessive;** 1: 20,000 births Hepatosplenomegaly, Pancytopenia Bone pain, Erlenmeyer flask deformity
Tay-Sachs disease	Hexosaminidase A	GM2 gangliosidesin neurons	**Autosomal recessive;** 1:320,000 Neurodegeneration, Developmental disability Early death
Metachromatic leukodystrophy (MLD)	Arylsulfatase A orprosaposin	Sulfatidecompounds in neural tissue	**Autosomal recessive** 1: 40,000 to 1:160,000 Demyelinisation in CNS, PNS: Mental retardation Motor dysfunction Ataxia Hyporeflexia Seizures

Disorders of lipid metabolism

Gaucher disease (Gaucher splenomegaly)

1882 French physician Philippe Gaucher; 1965,confirmed genetic mechanism

- **Type 1 GD** Non-neuropathic ; most common lipid met. Dis.; anytime in childhood or adulthood.
- **Type 2 GD** acute neuropathic form : brain, cord. fatality high; begin within 6 months of life
- **Type 3 GD** chronic neuropathic type: progresses slowly; any time in infancy or childhood.
- **Type 4 GD** perinatal lethal form ; most severe
- **Type 5 GD** cardiovascular type ;

Oc: Type 1 : 1: 50,000 live births; (Ashkenazi Jews) Type 2 and 3 1: 100,000 births

Sy:

- Abnormal enlargement of the spleen and liver (hepat splenomegaly) + abd press; liver cirrhosis; icterus
- Anemia; trombocytopenia (easy bruising)
- Leukocytopenia (risk of infection)
- Pulmonary discomfort; Osteoporosis; Arthritis
- Seizures, Mental disability, Increased muscle tone
- Muscle twitching Failure to thrive (observed in Type 2
- Difficulty swallowing, Abnormal ocular movements, including squint







Sphingomyelinosis

Niemann-Pick disease

Def: group of severe metabolic disorders manifested by sphingomyelin accumulation in lysosomes of various cells and tissues causing their enlargement and damage

Clin:

- hepatomegaly -> reduced appetite, abdominal distension pain.
- splenomegaly (enlarged spleen) -> thrombocytopenia
- cerebellum -> unsteady gait (ataxia), slurring of speech (dysarthria) and discoordinated swallowing (dysphagia).
- basal ganglia -> abnormal posturing of the limbs, trunk, and face (dystonia).
- brainstem -> impaired voluntary rapid eye movements (supranuclear gaze palsy).
- cerebral cortex -> loss of intellectual abilities, dementia and seizures.



Resources:
Niemann-Pick disease Types A and B - causes, symptoms, diagnosis, treatment, pathology; https://www.youtube.com/watch?v=RCOvoa4idyA
Niemann-Pick disease Type C - causes, symptoms, diagnosis, treatment, pathology https://www.youtube.com/watch?v=Fx28WYe-OW8

GM2 myelinosis

- **Tay–Sachs disease** destruction of nerve cells in the brain and spinal cord; **Early** 3-5 months; psychomotor degradation (losing ability to turn over, sit, or crawll; seizures, hearing loss, and inability to move, death 4y ; **juvenile** (death by age 15) **or late-onset** is less severe.



Resources:
Tay-Sachs disease - causes, symptoms, diagnosis, treatment, https://www.youtube.com/watch?v=2z3nSnBe8Vg&list=PLYUfYO5M87dXTD1n0BrgLjk3DjXJ-IPQ5

Fabry disease - causes, symptoms, diagnosis, treatment, pathology https://www.youtube.com/watch?v=AUkqYvZ9tn0

Fatty-acid metabolism disorders (FAOD)

- Carnitine Transport Defect
- Carnitine-Acylcarnitine Translocase (CACT) Deficiency
- Carnitine Palmitoyl Transferase I & II (CPT I & II) Deficiency
- 2,4 Dienoyl-CoA Reductase Deficiency
- Electron Transfer Flavoprotein (ETF) Dehydrogenase Deficiency (GAII & MADD)
- 3-Hydroxy-3 Methylglutaryl-CoA Lyase (HMG) Deficiency
- Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCAD deficiency)
- Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (LCHAD deficiency)
- Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCAD deficiency)
- Short-chain acyl-coenzyme A dehydrogenase deficiency (SCAD deficiency)
- 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (M/SCHAD deficiency)

Aminoaciduria

Phenylketonuria

- Def: Inherited disorder of phenylalanine metabolism
- Etio: AR, deficiency of phenylalanine hydroxylase 12q24.1 >1000 associated mutations
- Epi: 1:10,000 (European), 1:50,000 (African)
- Clin: Odor ("Musty"), Eczema,
- Brain accumulation of phenylalamin -->tremor
- developmental delay

Phenylketonuria - causes, symptoms, diagnosis, treatment, pathology
https://www.youtube.com/watch?v=HYg0Id-C0uQ
Phenylketonuria (PKU)
https://www.youtube.com/watch?v=mBNRuNsDJKU

Phenylketonuria



Urea cycle defects

Urea cycle defects

- **Ammonia** is a product of protein metabolism when if elevated has toxic effect to CNS.
- In terrestrial vertebrates ammonia is converted to **urea** in the liver via the **urea cycle** and is excreted in the **urine -** the first metabolic pathway be described by Krebs and Henseleit, in 1932
  - Carbamoyl phosphate is synthesized from NH4 + CO2, H2O, and ATP by carbamoyl phosphate synthetase
  - L-Ornithine reacts witgh carbamoyl phosphate to gove citruline
  - Argininosuccinate synthetase catalyzes the condensation of citrulline and aspartate to argininosuccinate.
  - This is cleaved by argininosuccinase into arginine and fumarate. Arginase hydrates L arginine to urea andL-Ornitine
- Mutations in genes encoding the enzymes of the urea cycle cause **5 hereditary disorders with high plasma levels of ammonium**
- The most common form is Xlinked OTC resulting from **mutations in the *OTC* gene located at Xp21.1**. It has 10 exons spanning 73 kb of DNA.



KEY TO ENZYMES (Circled Numbers)

1. Carbamoyl-phosphate synthase (ammonia)
2. Ornithine carbamoyltransferase
3. Argininosuccinate synthase
4. Argininosuccinate lyase
5. Arginase


Urea Cycle
fumarate
arginine
arginino-
succinate
argininosuccinase
EC 4.3.2.1
PPi + AMP
argininosuccinate
synthetase
EC 6.3.4.5
arginase
EC 3.5.3.1
H2O
aspartate
+ ATP
+ citrulline
(cytosol)
urea
+
ornithine
(cytosol)
cytosol
inner mitochondrial membrane
matrix
citrulline
(mitochondrial
matrix)
Pi
carbamoyl phosphate
(CbmP)
ornithine
transcarbamoylase
EC 2.1.3.3
+
ornithine
(mitochondrial
matrix)
2 ATP + NH3 + HCO3-
2 ADP + Pi + H+
carbamoyl phosphate synthetase I
EC 6.3.4.16

Urea cycle defects (UCD)

	UCD	Enzyme Deficiency	Symptoms/Comments
1.	**Type I Hyperammonemia, CPSD**	Carbamoylphosphate synthetase I	24h–72h after birth infant becomes lethargic, needs stimulation to feed, vomiting, hypothermia, hyperventilation; hyperamonemia; **T: arginine which activates *N*-acetylglutamate synthetase**
2.	***N*-acetylglutamate synthetase deficiency**	*N*-acetylglutamate synthetase	mild to severe hyperammonemia associated with deep coma, acidosis, recurrent diarrhea, ataxia, hypoglycemia, hyperornithinemia: **T: administration of carbamoyl glutamate to activate CPS I**
3.	**Type 2 Hyperammonemia, OTCD**	Ornithine transcarbamoylase	most common, X-linked UCD, ammonia and amino acids elevated in serum, increased serum orotic acid **T: high carbohydrate, low protein diet, ammonia detoxification (sodium phenylacetate or sodium benzoate)**
4.	**Classic citrullinemia, ASD**	Argininosuccinate synthetase	episodic hyperammonemia, vomiting, lethargy, ataxia, siezures, eventual coma: **T: arginine administration** to enhance citrulline excretion, **ammonia detoxification (sodium benzoate)**
5.	**Argininosuccinic aciduria, ALD**	Argininosuccinate lyase	episodic symptoms similar to classic citrullinemia, elevated plasma and cerebral spinal fluid argininosuccinate: **T:diet with arginine and sodium benzoate**
6.	**Hyperargininemia, AD**	Arginase	rare UCD, progressive spastic quadriplegia and mental retardation, ammonia + arginine high in cerebral spinal fluid and serum, arginine, lysine and ornithine high in urine: **T: diet of essential amino acids excluding arginine, low protein diet**

Ammonia detoxification + low protein diet !!!

Symptoms of hyperammonemia

- vomiting, seizures, headache,
- mental status changes, (lethargy, coma)
- compensatory hyperventilation (fast breaths; compensates acidosis but may lead to respiratory alkalosis)
- muscle hypotonia/ hypertonia, ataxia, tremor, seisures



Primary hyperammonemia = caused by inborn errors + reduced activity of the enzymes in the urea cycle metabolism (UCD)
= hyperammonemia + hypoglycemia with/out metabolic acidosis

Secondary hyperammonemia = inborn refect of enzymes that are not part of the urea cycle (e.g. .propionic acidemia, methylmalonic acidemia) or dysfunction of cells that make major contributions to metabolism (e.g. hepatic failure).

- organic acidurias = **hyperammonemia + anion gap metabolic acidosis**
  - fatty acid oxidation disorder (FAODs)
  - hyperornithinemia-hyperammonemia-homocitrullinemia syndrome,
  - pyruvate carboxylase deficiency,
  - hyperammonemia-hyperinsulinemia syndrome.
  - Sepsis; liver failure; medications: valproate; trasient hyperammonemia of the newborn (resolves perinatally)

Hyperammonemia

= is a metabolic disturbance characterised by an excess of ammonia in the blood.

It is a dangerous condition that may lead to encephalopathy and death.

Diagnostic“spider“ for hyperammonemia in the newborns







Metabolic disorders of hem

Porphyrias

Group of enzyme deficiencies of haem synthesis leading to accummulation of various intermediates porthyrins affecting the skin, liver or nervous sytem: **a) inherited** (AD, AR, X-linked dominant, b) **acquired** (hemochromatosis,

Erythropoietic porphyria:
X-linked dominant protoporphyria (XLDPP),
Congenital erythropoietic porphyria (CEP)
Erythropoietic protoporphyria (EPP)

Hepatic porphyria:
Aminolevulinate dehydratase deficiency porphyria (ALADP)
Acute intermittent porphyria (AIP)
Porphyria cutanea tarda (PCT)
Hereditary coproporphyria (HCP) variegate porphyria (VP)

Cutaneous porphyria
Congenital erythropoietic porphyria (CEP)
X-linked dominant protoporphyria (XLDPP),)
Porphyria cutanea tarda (PCT)
Erythropoietic protoporphyria (EPP)
Hereditary coproporphyria (HCP)
Variegate porphyria (VP)



Acute porphyrias

- **Types:** acute intermittent porphyria (AIP), variegate porphyria (VP), aminolevulinic acid dehydratase deficiency porphyria (ALAD) and hereditary coproporphyria (HCP).
- **Clinic: predominantly neurological symptoms**
- attacks (days to weeks) triggered by alcohol, smoking, hormonal changes, fasting, stress, or certain medications; rapid in onset, last a short time
- affect CNS nervous system; episodic acute attacks; resolve once the attack passes
  - Light forms: abdominal & chest pain, vomiting, confusion, constipation, fever, hypertension , tachycardia. skin is affected, blisters or itching may occur with sunlight exposure
  - Severe forms: motor peripheral neuropathy, muscle weakness, quadriplegia; CNS: anxiety, confusion, hallucinations, seizures and coma. and, very rarely psychosis

Cutanous porphyria



Porhyria cutanea tarda



Acute intermittent porhyria

Change in urine color after sun exposure

Porphyrins are photoactive molecules



Chronic porphyrias

- **Types**: X-linked dominant protoporphyria (XLDPP), congenital erythropoietic porphyria (CEP), porphyria cutanea tarda (PCT), and erythropoietic protoporphyria (EPP).
- **Clinic:** primary manifestation is in skin disease. **cutaneous porphyrias;** 2 distinct patterns
- **(A) Immediate photosensitivity**: (XLDPP, EPP.) 30 min after sun exposure : severe pain, burning, and discomfort in exposed areas (redness and swelling).
- **(B) Vesiculo-erosive skin disease** CEP, PCT, VP + HCP. blisters (vesicles)/open sores (erosions) noted in patients in sun-exposed areas (face, back of the hands).
  - VP + HCP: Milder disease - skin fragility, blisters and erosions, particularly after minor knocks; heal slowly, small scars that may be lighter or darker than normal skin.
  - PCT: More severe - darkening of exposed skin, hypertrichosis
  - CEP, HEP most severe disease - hepatoerythropoietic porphyria (HEP); severe shortening of digits, loss of skin appendages such as hair and nails, severe scarring of the skin with progressive disappearance of ears, lips, and nose; deformed, discolored teeth or gum and eye abnormalities.

Porphyrias







Hepatoerythropoietic porphyria (HEP)